

# Surgical Treatments for Lumbar Spine Diseases: A Systematic Review and Meta-Analysis

Kanthika Wasinpongwanich<sup>1</sup> · Tanawin Nopsopon<sup>2</sup> · Krit Pongpirul<sup>2,3,4</sup>

<sup>1</sup> Department of Orthopedics, Faculty of Medicine, Suranaree University of Technology, Nakhon Ratchasima, Thailand

<sup>2</sup> Department of Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

<sup>3</sup> Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

<sup>4</sup> Bumrungrad International Hospital, Bangkok, Thailand

**Corresponding author: Krit Pongpirul**

Email: doctorkrit@gmail.com

**ORCID ID**

KW: [0000-0002-2649-2846](https://orcid.org/0000-0002-2649-2846)

TN: 0000-0003-0428-973X

KP: 0000-0003-3818-9761

## Abstract

**Purpose** Surgical treatment is mandatory in some patients with lumbar spine diseases. To obtain spine fusion, many operative techniques were developed with different fusion rates and clinical results. This study aimed to collect randomized controlled trial (RCT) data to compare fusion rate, clinical outcomes, complications among Transforaminal Lumbar Interbody Fusion (TLIF), and other techniques for lumbar spine diseases.

**Methods** A systematic literature search of PubMed, Embase, Scopus, Web of Science, and CENTRAL databases was searched for studies up to 13 February 2020. The meta-analysis was done using a random-effects model. Pooled risk ratio (RR) or mean difference (MD) with a 95% confidence interval of fusion rate, clinical outcomes, and complication in TLIF and other techniques for lumbar diseases.

**Results** The literature search identified 3,682 potential studies, 15 RCTs (915 patients) were met our inclusion criteria and were included in the meta-analysis. Compared to other techniques, TLIF had slightly lower fusion rate (RR=0.84 [95% CI 0.72, 0.97],  $p=0.02$ ,  $I^2=0.0\%$ ) at 1-year follow-up while there was no difference on fusion rate at 2-year follow up (RR=1.06 [95% CI 0.96, 1.18],  $p=0.27$ ,  $I^2=69.0\%$ ). The estimated risk ratio of total adverse events (RR=0.90 [95% CI 0.59, 1.38],  $p=0.63$ ,  $I^2=0.0\%$ ) and revision rate (RR=0.78 [95% CI 0.34, 1.79],  $p=0.56$ ,  $I^2=39.0\%$ ) showed no difference. TLIF had approximately half an hour more operative time than other techniques (MD=31.88 [95% CI 5.33, 58.44],  $p=0.02$ ,  $I^2=92.0\%$ ). There was no significant difference between TLIF and other techniques in terms of the blood loss, and clinical outcomes.

**Conclusions** Besides fusion rate at 1-year follow-up and operative time, our study demonstrated similar outcomes of TLIF with other techniques for lumbar diseases in regard to fusion rate, clinical outcomes, and complications.

**Keywords:** Transforaminal Lumbar Interbody Fusion • Lumbar disease • Meta-analysis • Spondylolisthesis • Degenerative lumbar disease

## Introduction

Surgical treatment is mandatory in some patients with lumbar spine diseases. To obtain spine fusion, many operative techniques have been developed with different fusion rates and clinical results. Cloward et al. first described Posterolateral Lumbar Interbody Fusion (PLIF) in 1952 [1] whereas Harm & Rollinger introduced Transforaminal Lumbar Interbody Fusion (TLIF) three decades later [2]. In early 2002, the minimally invasive surgical (MIS) approach was promoted to TLIF by Foley and Lefkowitz to improve peri-postoperative morbidity and clinical results [3]. For anterior lumbar interbody fusion has a long history in the tuberculous spine however the technique was adapted to other lumbar spine diseases [4]. Ozgur et al. describe a novel spine procedure called the Extreme Lateral Interbody Fusion or XLIF in 2006 [5].

Several systematic reviews compared either MIS TLIF or Open TLIF with other techniques e.g. MIS vs open TLIF/PLIF [6], TLIF vs ALIF [7], MIS TLIF vs LLIF [8], TLIF vs PLIF [9], TLIF vs PLF [10]. The studies were conducted around 2014-2018 [6-8,10-14]. Most of them compared 1 or 2 techniques with TLIF for lumbar spine diseases [6-14]. Half of them concluded the level of evidence on their study was low and need more randomized control trials (RCTs) [6-8,10,15]. The fusion rates, clinical outcomes, and complications among operative techniques for lumbar spine diseases have been inconclusive. As time passed, the learning curve of different techniques was theoretically decreased and more RCTs were recently propagated [16-30].

This systematic review and meta-analysis aimed to offer updated results based on fusion rate, clinical outcomes, and complications between TLIF, decompression alone (no fusion), posterolateral fusion, and other interbody fusion (PLIF, ALIF, XLIF).

## Methods

This study was conducted following the recommendations of the Preferred Reporting Items of Systematic Reviews and Meta-Analyses (PRISMA) statement. We prospectively registered the systematic review with PROSPERO International Prospective Register of Ongoing Systematic Reviews (Registration number: CRD42020186858).

## Search strategy

A systematic literature search of PubMed, Embase, Scopus, Web of Science, and CENTRAL databases were searched for studies published between January 2010 and January 2019. The electronic databases were searched up

to 13 February 2020. The reproducible search strategy was presented in detail in the Supplement. Besides, the reference lists of included articles were searched, as well as related citations from other journals via Google Scholar.

## Study selection

Only randomized controlled trials comparing lumbar interbody fusion with posterolateral fusion and/or other lumbar interbody fusion were anticipated in this review. Inclusion criteria were established as follows: (1) the studies with a population of patient age >18 years old (2) randomized controlled trial investigating lumbar spine disease treated with any Lumbar Interbody Fusion or Posterolateral Fusion or No fusion, (3) the study included at least one outcome (fusion rate, disability and pain or complications, operative time, blood loss, hospital length of stay). Exclusion criteria were (1) biomechanical and cadaveric studies, (2) paper that is not in English, (3) duplicated studies.

The title and abstracts of each study were independently reviewed by 2 authors (KW, TN) to assess for inclusion in the meta-analysis. For studies that meet the inclusion criteria, 2 reviewers (KW, TN) independently reviewed the full manuscripts. Discrepancies between the 2 reviewers were resolved by discussion until reach consensus among the authors. In accordance with PRISMA guidelines, the process is presented in a flow chart [31] (Fig.1)

## Data extraction

The following data items were independently extracted by two authors (KW, TN) from the included studies; study design (author, year, country), study population (number of included patients, age, indication for surgery), Visual Analog Score (VAS) for back and leg pain, Oswestry Disability Index (ODI), parameters concerning operation (operative time, length of hospital stay, blood loss, revision) Complications (total adverse events, infection, dural tear, etc.). Discrepancies were resolved by consensus.

## Quality assessment

The authors worked independently to assess the risk of bias in the included trials using the Cochrane Risk of Bias tool 2.0 for a randomized control trial study[32]. We assessed the randomization process, deviations from intended intervention, missing outcome data, measurement of the outcome, selection of the reported result. We assigned each domain as a low risk of bias, some concerns, and a high risk of bias. We contacted the authors if there was not enough information to assess. If the trial authors did not respond within 14 days, we conducted the assessment using

available data. We resolved the disagreement through discussion. We presented our risk of bias assessment in Figs. 2 and 3.

## Statistical Analysis

The primary outcome was fusion rate, total adverse events, and revision rate. The outcomes measured were the mean difference for VAS back and leg pain, Oswestry Disability Index (ODI) score, operative time, blood loss, length of hospital stay with associated 95% CI. Fusion rate, total adverse events, infection rate, revision rate, dural tear were reported as the risk ratio (RR) with 95% CI. The results of the studies were included in the meta-analysis and presented in a forest plot, which also showed statistical powers, confidence intervals, and heterogeneity. The variability within-a study and between studies was assessed by an  $I^2$  estimate of heterogeneity. We regarded level of heterogeneity for  $I^2$  statistic as defined in chapter 9 of the Cochrane Handbook for Systematic Reviews of Interventions: 0–40% might not be important; 30–60% may represent moderate heterogeneity; 50–90% may represent substantial heterogeneity; 75–100% considerable heterogeneity. The random-effects meta-analysis by DerSimonian and Laird method was used as clinical, methodological, and statistical heterogeneity encountered. Prespecified subgroup analyses by type of comparators were performed. We assessed publication bias by computing each study effect size against standard error and plotted it as a funnel plot to assess asymmetry visually. The significant asymmetry indicated the possibility of publication bias or heterogeneity. The meta-analysis was performed using Revman 5.3 (Cochrane Collaboration, Oxford, UK).

## Results

### Systematic Review

A systematic search identified 3,682 potential English articles, 1,957 were removed due to duplication. Two reviewers assessed the title and abstracts of 1,725 studies which 144 manuscripts remained for full-text assessment. Eventually, 18 RCTs were met the inclusion criteria. 2 RCTs were considered the same population of the TLIF group therefore one study was excluded from the analysis. The studies which did not report the variation were excluded. A preferred reporting Items for Systematic Reviews and Meta-Analyses diagram is shown in Fig. 1.

There were 15 RCTs included with 915 patients (470 TLIF, 258 PLF, 87 PLIF, 26 ALIF, 29 XLIF, 45 no fusion). The TLIF group in the 2 studies was in addition to posterolateral fusion (PLF). Publication years ranged

118 from 2013 to 2019. Two studies reported outcome 1-year follow-up the other reported at least 2-year follow-up.

119 Study characteristics are provided in Table 1.

120

121 **Table 1** Study characteristics

Author	Surgical technique	TLIF, n	Other techniques, n	Follow up
Challier 2017	PLF+TLIF vs PLF	30	30	2y
Christensen 2014	TLIF vs PLF	51	49	1y, 2y
ElShazly 2013	Discectomy+TLIF vs no fusion	15	15	2y
	Discectomy+TLIF vs Discectomy+PLF	15	15	2y
Etemadifar 2016	PLF+TLIF vs PLF	25	25	1.5m, 3m, 6m, 1y, 2y
Fariborz 2016	TLIF vs PLIF	30	30	6m, 1y
	TLIF vs PLF	30	30	6m, 1y
	TLIF vs no fusion+instrumentation	30	30	6m, 1y
Hoff 2016	TLIF vs ALIF	24	26	1y, 3y
Høy 2013*	TLIF vs PLF	51	49	1y, 2y
Høy 2017*	TLIF vs PLF	44	44	1y, 2y, 5-10y
Høy 2019*	TLIF vs PLF	51	49	1y, 2y
Isaacs 2016**	TLIF vs XLIF	26	29	1y, 2y
Jalalpour 2015	TLIF vs PLF	68	67	1y, 2y
Li 2013	TLIF vs PLF	19	18	2-5y
Putzier 2016	TLIF vs PLIF	24	23	1y
Sembrano 2016**	TLIF vs XLIF	55	26	1y
Yang 2016	TLIF vs PLIF	32	34	3m, 1-2y

122 \* same sample group, \*\* same sample group

123

## Quality assessment

For the risk of bias assessment, the included randomized controlled trials had a relatively high percentage of low risk in the randomization process and deviations from intended intervention domains. All included RCTs had some concerns risk of bias on measurement of the outcome. There was some high risk of bias in deviations from intended interventions and selection of the reported result domains. Detailed risk-of-bias assessment for included randomized controlled trials was provided in Fig. 2. A summary of the percentages of RCTs which were at low, some concerns, and high risk for each risk of bias domain was presented in Fig. 3. The funnel plots showed no significant asymmetry which highlighted no evidence of publication bias on the fusion rate, total adverse events, and revision rate. (Supplementary File 1).

## Meta-analysis

A total of 15 included studies were included in the meta-analysis with 915 patients (470 TLIF, 258 PLF, 87 PLIF, 26 ALIF, 29 XLIF, 45 no fusion).

## Fusion rate

Fusion rate was 72.7% on TLIF group at 1 year follow up whereas 87.03% fusion rate was reported on other techniques. TLIF had slightly lower fusion rate at 1 year follow up compared to other techniques ( $RR=0.84$  [95% CI 0.72, 0.97],  $p=0.02$ ,  $I^2=0.0\%$ ) (Fig. 4). However, the fusion rate at 2 years was not shown any statistically significant differences ( $RR=1.06$  [95% CI 0.96, 1.18],  $p=0.27$ ,  $I^2=69.0\%$ ) as shown in Fig. 5.

## Complications: total adverse events, revision, infection, and dural tear

Total adverse events were reported in 10 studies. TLIF had similar total adverse events compared with PLIF, XLIF and no fusion group ( $RR=0.90$  [95% CI 0.59, 1.38],  $p=0.63$ ,  $I^2=0.0\%$ ) as shown in Fig. 6. For the revision needed after surgical procedures, the results indicated a different revision rate among groups. ( $RR=0.78$  [95% CI 0.34, 1.79],  $p=0.56$ ,  $I^2=39.0\%$ ) as shown in Fig. 7.

Infection was reported in 6 studies, overall infection was similar among groups ( $RR=1.78$  [95% CI 0.58, 5.46],  $p=0.31$ ,  $I^2=0.0\%$ ). More infection reported in the TLIF group but was not statistically significant. The dural



tear was higher in other techniques esp. XLIF group but not reach statistically significant (RR=1.19 [95% CI 0.49, 2.89],  $p=0.70$ ,  $I^2=0.0\%$ ). The results of secondary outcomes were reported as shown in Table 2.

### **Operative time**

ALIF, PLF, no fusion group has shorter operative time whereas PLIF has longer operative time compared to TLIF. The pooled mean difference in operative time of other techniques was 31.88 minutes shorter than TLIF (MD=31.88 [95% CI 5.33, 58.44],  $p=0.02$ ,  $I^2=92.0\%$ )

### **Blood loss**

TLIF has less blood loss than PLIF 88.80 ml. No fusion has less blood loss among groups. Pooled mean difference in blood loss showed no significant difference (MD=191.00 [95%CI -53.93, 435.93],  $p=0.13$ ,  $I^2=90.0\%$ ).

### **Length of hospital stay**

Length of hospital stay between subgroup were not significantly difference. Pooled mean difference in hospital stay was 0.12. (MD=0.12 [95% CI -0.30, 0.54],  $p=0.58$ ,  $I^2=0.0\%$ ).

### **Back and leg pain**

Visual Analog Scale (VAS) for back were extracted from 6 studies. There was no difference between back pain at last follow up in TLIF and other techniques group (MD=0.13 [95% CI -0.40, 0.66],  $p=0.62$ ,  $I^2=82.0\%$ ). ALIF (MD=1.20 [95% CI 0.53, 1.87],  $p<0.01$ ) and no fusion techniques (MD=0.60 [95% CI 0.08, 1.12],  $p=0.02$ ) were shown less back pain at last follow up. Visual Analog Scale (VAS) for leg was extracted from only PLF studies. There was no difference between leg pain at last follow up in TLIF and PLF group (MD=-0.07 [95% CI -1.43, 1.30],  $p=0.92$ ,  $I^2=77.0\%$ ).

### **ODI**

No difference in ODI was observed (MD=-4.82 [95% CI -11.72, 2.08],  $p=0.17$ ,  $I^2=90.0\%$ ). Compared to TLIF, no fusion group had higher ODI at last follow up (MD=-41.30 [95% CI -50.15, -32.45],  $p<0.001$ ).

171 **Table 2** Secondary outcomes

Outcomes	Studies	Patients	Statistical Method	Effect size [95% CI]
Infection	6	433	IV, random, 95% CI	RR=1.78 [95% CI 0.58, 5.46], $p=0.31$ , $I^2=0.0\%$
Dural tear	7	570	IV, random, 95% CI	RR=1.19 [95% CI 0.49, 2.89], $p=0.70$ , $I^2=0.0\%$
Operative time	6	353	IV, random, 95% CI	MD=31.88 [95% CI 5.33, 58.44], $p=0.02$ , $I^2=92.0\%$
Blood loss	4	248	IV, random, 95% CI	191.00 [95% CI -53.93, 435.93], $p=0.13$ , $I^2=90.0\%$
Length of Hospital stay	3	200	IV, random, 95% CI	MD=0.12 [95% CI -0.30, 0.54], $p=0.58$ , $I^2=0.0\%$
VAS back at last follow up	6	335	IV, random, 95% CI	MD=0.13 [95% CI -0.40, 0.66], $p=0.62$ , $I^2=82.0\%$
VAS leg at last follow up	2	150	IV, random, 95% CI	MD=-0.07 [95% CI -1.43, 1.30], $p=0.92$ , $I^2=77.0\%$
ODI at last follow up	7	521	IV, random, 95% CI	MD=-4.82 [95% CI -11.72, 2.08], $p=0.17$ , $I^2=90.0\%$

172 *CI* confidence interval; *IV* inverse variance; *MD* mean difference; *RR* risk ratio; *VAS* Visual Analog Scale

## 173 Discussion

174 Patients with degenerative lumbar spine disease require surgical intervention when the conservative treatments  
175 failed [7–10]. The operative methods are varyingly selected among spine surgeons. Therefore, the clinical outcomes  
176 esp. fusion rate, and other outcomes were reported in different studies. This systematic review and meta-analysis are  
177 to investigate the benefits and risks of lumbar interbody fusion, no fusion, and posterolateral fusion by comparing  
178 the fusion rate, clinical outcomes (VAS back, VAS leg, and ODI), parameters concerning operation (operative time,  
179 length of hospital stay, blood loss, revision) and complications in TLIF and other techniques for lumbar diseases.

Findings from our study were similar to the previous systematic review that reported 89.1% fusion rate and 12.5% reoperation rate [33]. Manzur et al. reported 85.6% fusion rate on LLIF [34]. Similar to Tao et al. study which PLIF compared with TLIF, demonstrated similar outcomes and complications [35].

Surgical complications evaluated by total adverse events were not shown statistically significant differences among lumbar interbody fusion, no fusion, and posterolateral fusion. However, TLIF seems to be safer than PLIF and ALIF in neural, spinal and vascular events, similar to previous study by Chi et al. [36]. Nonetheless, Yavin et al. demonstrated more complications on fusion group compared to non-fusion group [37].

### **Strength and limitations**

The strength of this study was that we included only RCTs that showed no significant asymmetry which highlighted no evidence of publication bias on the fusion rate, total adverse events, and revision rate. However, the small number of RCT on TLIF was the limitation of our study. The heterogeneity of the enrolled studies was another limitation. Furthermore, sample group of some the same population as shown in table 1. We try to reduce the bias by excluded the repeated data from the analysis.

The overall lumbar spine disease were heterogenous in approach for each studies which may complicated the results. Different surgical approach, experience and outcome measure were also observed. The outcomes were referred to single level surgery which couldn't apply to multi-level diseases.

### **Conclusion**

The present systematic review and meta-analysis of RCTS demonstrated lower fusion rate of TLIF at 1 year but similar outcomes of TLIF with other techniques (no fusion, PLF, PLIF, ALIF, XLIF) for lumbar diseases in regards to fusion rate at 2 years, clinical outcomes and complications. Anticipate in randomized control trials are needed for selecting a surgical approach for lumbar spinal diseases.

**Authors' contribution** KW and KP contributed to the study conception and design. Material preparation and data collection were performed by KW and TN. Data analysis was performed by TN. All authors wrote the first draft of the manuscript, revised, and approved the final manuscript.

205     **Funding** No funding was received for this study.

206     **Data Availability Statement** All data generated or analyzed during this study are included in this published article  
207     (and its supplementary information files).

208     **Compliance with ethical standards**

209     **Conflicts of interest** All authors declare that there are no conflicts of interest.

210

# References

1. Cloward RB. The treatment of ruptured lumbar intervertebral discs by vertebral body fusion. I. Indications, operative technique, after care. J Neurosurg. 1953 Mar;10(2):154-68. doi: 10.3171/jns.1953.10.2.0154. PMID: 13035484.
2. Harms J, Rolinger H. Die operative Behandlung der Spondylolisthese durch dorsale Aufrichtung und ventrale Verblockung [A one-stager procedure in operative treatment of spondylolistheses: dorsal traction-reposition and anterior fusion (author's transl)]. Z Orthop Ihre Grenzgeb. 1982 May-Jun;120(3):343-7. German. doi: 10.1055/s-2008-1051624. PMID: 7113376.
3. Foley KT, Lefkowitz MA. Advances in minimally invasive spine surgery. Clin Neurosurg. 2002;49:499-517. PMID: 12506566.
4. Choy WJ, Abi-Hanna D, Cassar LP, Hardcastle P, Phan K, Mobbs RJ. History of Integral Fixation for Anterior Lumbar Interbody Fusion (ALIF): The Hartshill Horseshoe. World Neurosurg. 2019 Sep;129:394-400. doi: 10.1016/j.wneu.2019.06.134. Epub 2019 Jun 27. PMID: 31254709.
5. Ozgur BM, Aryan HE, Pimenta L, Taylor WR. Extreme Lateral Interbody Fusion (XLIF): a novel surgical technique for anterior lumbar interbody fusion. Spine J. 2006 Jul-Aug;6(4):435-43. doi: 10.1016/j.spinee.2005.08.012. PMID: 16825052.
6. Goldstein CL, Macwan K, Sundararajan K, Rampersaud YR. Perioperative outcomes and adverse events of minimally invasive versus open posterior lumbar fusion: meta-analysis and systematic review. J Neurosurg Spine. 2016 Mar;24(3):416-27. doi: 10.3171/2015.2.SPINE14973. Epub 2015 Nov 13. PMID: 26565767.
7. Phan K, Thayaparan GK, Mobbs RJ. Anterior lumbar interbody fusion versus transforaminal lumbar interbody fusion--systematic review and meta-analysis. Br J Neurosurg. 2015;29(5):705-11. doi: 10.3109/02688697.2015.1036838. Epub 2015 May 12. PMID: 25968330.
8. Joseph JR, Smith BW, La Marca F, Park P. Comparison of complication rates of minimally invasive transforaminal lumbar interbody fusion and lateral lumbar interbody fusion: a systematic review of the literature. Neurosurg Focus. 2015 Oct;39(4):E4. doi: 10.3171/2015.7.FOCUS15278. PMID: 26424344.
9. Chi KY, Cheng SH, Kuo YK, Lin EY, Kang YN. Safety of Lumbar Interbody Fusion Procedures for Degenerative Disc Disease: A Systematic Review With Network Meta-Analysis of Prospective Studies.


- Global Spine J. 2020 Jul 28;2192568220938024. doi: 10.1177/2192568220938024. Epub ahead of print. PMID: 32720524.
10. Zhang BF, Ge CY, Zheng BL, Hao DJ. Transforaminal lumbar interbody fusion versus posterolateral fusion in degenerative lumbar spondylosis: A meta-analysis. *Medicine (Baltimore)*. 2016 Oct;95(40):e4995. doi: 10.1097/MD.0000000000004995. PMID: 27749558; PMCID: PMC5059060.
11. Lan T, Hu SY, Zhang YT, Zheng YC, Zhang R, Shen Z, Yang XJ. Comparison Between Posterior Lumbar Interbody Fusion and Transforaminal Lumbar Interbody Fusion for the Treatment of Lumbar Degenerative Diseases: A Systematic Review and Meta-Analysis. *World Neurosurg*. 2018 Apr;112:86-93. doi: 10.1016/j.wneu.2018.01.021. Epub 2018 Jan 31. PMID: 29367001.
12. Keorochana G, Setrkraising K, Woratanarat P, Arirachakaran A, Kongtharvonskul J. Clinical outcomes after minimally invasive transforaminal lumbar interbody fusion and lateral lumbar interbody fusion for treatment of degenerative lumbar disease: a systematic review and meta-analysis. *Neurosurg Rev*. 2018 Jul;41(3):755-770. doi: 10.1007/s10143-016-0806-8. Epub 2016 Dec 24. PMID: 28013419.
13. Zhang Q, Yuan Z, Zhou M, Liu H, Xu Y, Ren Y. A comparison of posterior lumbar interbody fusion and transforaminal lumbar interbody fusion: a literature review and meta-analysis. *BMC Musculoskelet Disord*. 2014 Nov 5;15:367. doi: 10.1186/1471-2474-15-367. PMID: 25373605; PMCID: PMC4232693.
14. Lan T, Hu SY, Zhang YT, Zheng YC, Zhang R, Shen Z, Yang XJ. Comparison Between Posterior Lumbar Interbody Fusion and Transforaminal Lumbar Interbody Fusion for the Treatment of Lumbar Degenerative Diseases: A Systematic Review and Meta-Analysis. *World Neurosurg*. 2018 Apr;112:86-93. doi: 10.1016/j.wneu.2018.01.021. Epub 2018 Jan 31. PMID: 29367001.
15. Teng I, Han J, Phan K, Mobbs R. A meta-analysis comparing ALIF, PLIF, TLIF and LLIF. *J Clin Neurosci*. 2017 Oct;44:11-17. doi: 10.1016/j.jocn.2017.06.013. Epub 2017 Jul 1. PMID: 28676316.
16. Challier V, Boissiere L, Obeid I, Vital JM, Castelain JE, Bénard A, Ong N, Ghailane S, Pointillart V, Mazas S, Mariey R, Gille O. One-Level Lumbar Degenerative Spondylolisthesis and Posterior Approach: Is Transforaminal Lateral Interbody Fusion Mandatory?: A Randomized Controlled Trial With 2-Year Follow-Up. *Spine (Phila Pa 1976)*. 2017 Apr 15;42(8):531-539. doi: 10.1097/BRS.0000000000001857. PMID: 27548582.


17. Christensen A, Høy K, Bünger C, Helmig P, Hansen ES, Andersen T, Søgaaard R. Transforaminal lumbar interbody fusion vs. posterolateral instrumented fusion: cost-utility evaluation along side an RCT with a 2-year follow-up. *Eur Spine J*. 2014 May;23(5):1137-43. doi: 10.1007/s00586-014-3238-6. Epub 2014 Feb 21. PMID: 24557326.
18. El Shazly AA, El Wardany MA, Morsi AM. Recurrent lumbar disc herniation: A prospective comparative study of three surgical management procedures. *Asian J Neurosurg*. 2013;8(3):139-146. doi:10.4103/1793-5482.121685
19. Etemadifar MR, Hadi A, Masouleh MF. Posterolateral instrumented fusion with and without transforaminal lumbar interbody fusion for the treatment of adult isthmic spondylolisthesis: A randomized clinical trial with 2-year follow-up. *J Craniovertebr Junction Spine*. 2016 Jan-Mar;7(1):43-9. doi: 10.4103/0974-8237.176623. PMID: 27041885; PMCID: PMC4790148.
20. Fariborz, Samini MD; Gharedaghi, Mohammad MD; Khosravi, Abbas F. MD; Samini, Mohammad MS Comparison of Results of 4 Methods of Surgery in Grade 1 Lumbosacral Spondylolisthesis, *Neurosurgery Quarterly*: February 2016 - Volume 26 - Issue 1 - p 14-18 doi: 10.1097/WNQ.0000000000000197
21. Hoff EK, Strube P, Pumberger M, Zahn RK, Putzier M. ALIF and total disc replacement versus 2-level circumferential fusion with TLIF: a prospective, randomized, clinical and radiological trial. *Eur Spine J*. 2016 May;25(5):1558-1566. doi: 10.1007/s00586-015-3852-y. Epub 2015 Mar 7. PMID: 25749689.
22. Høy K, Bünger C, Niederman B, Helmig P, Hansen ES, Li H, Andersen T. Transforaminal lumbar interbody fusion (TLIF) versus posterolateral instrumented fusion (PLF) in degenerative lumbar disorders: a randomized clinical trial with 2-year follow-up. *Eur Spine J*. 2013 Sep;22(9):2022-9
23. Høy K, Truong K, Andersen T, Bünger C. Addition of TLIF does not improve outcome over standard posterior instrumented fusion. 5-10 years long-term Follow-up: results from a RCT. *Eur Spine J*. 2017 Mar;26(3):658-665. doi: 10.1007/s00586-016-4592-3. Epub 2016 May 7. PMID: 27155825.
24. Høy K, Grycel B, Andersen T, Bünger C. Does transforaminal lumbar interbody fusion produce leg pain?- Results from a RCT. *J Orthop Surg (Hong Kong)*. 2019 Sep-Dec;27(3):2309499019869469. doi: 10.1177/2309499019869469. PMID: 31530081.
25. Isaacs RE, Sembrano JN, Tohmeh AG; SOLAS Degenerative Study Group. Two-Year Comparative Outcomes of MIS Lateral and MIS Transforaminal Interbody Fusion in the Treatment of Degenerative

- Spondylolisthesis: Part II: Radiographic Findings. *Spine (Phila Pa 1976)*. 2016 Apr;41 Suppl 8:S133-44. doi: 10.1097/BRS.0000000000001472. PMID: 26839992.
26. Jalalpour K, Neumann P, Johansson C, Hedlund R. A Randomized Controlled Trial Comparing Transforaminal Lumbar Interbody Fusion and Uninstrumented Posterolateral Fusion in the Degenerative Lumbar Spine. *Global Spine J*. 2015 Aug;5(4):322-8. doi: 10.1055/s-0035-1549033.
27. Li FC, Chen QX, Chen WS, Xu K, Wu QH, Chen G. Posterolateral lumbar fusion versus transforaminal lumbar interbody fusion for the treatment of degenerative lumbar scoliosis. *J Clin Neurosci*. 2013 Sep;20(9):1241-5. doi: 10.1016/j.jocn.2012.10.031. Epub 2013 Jul 1. PMID: 23827174.
28. Putzier M, Hartwig T, Hoff EK, Streitparth F, Strube P. Minimally invasive TLIF leads to increased muscle sparing of the multifidus muscle but not the longissimus muscle compared with conventional PLIF-a prospective randomized clinical trial. *Spine J*. 2016 Jul;16(7):811-9. doi: 10.1016/j.spinee.2015.07.460. Epub 2015 Jul 30. PMID: 26235468.
29. Sembrano JN, Tohmeh A, Isaacs R; SOLAS Degenerative Study Group. Two-year Comparative Outcomes of MIS Lateral and MIS Transforaminal Interbody Fusion in the Treatment of Degenerative Spondylolisthesis: Part I: Clinical Findings. *Spine (Phila Pa 1976)*. 2016 Apr;41 Suppl 8:S123-32. doi: 10.1097/BRS.0000000000001471. PMID: 26825788.
30. Yang EZ, Xu JG, Liu XK, Jin GY, Xiao W, Zeng BF, Lian XF. An RCT study comparing the clinical and radiological outcomes with the use of PLIF or TLIF after instrumented reduction in adult isthmic spondylolisthesis. *Eur Spine J*. 2016 May;25(5):1587-1594. doi: 10.1007/s00586-015-4341-z. Epub 2015 Dec 9. PMID: 26649555.
31. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). *Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement*. *PLoS Med* 6(7): e1000097. doi:10.1371/journal.pmed1000097
32. Sterne J, Savović J, Page M et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ* 366:i4898
33. Phillips FM, Slosar PJ, Youssef JA, Andersson G, Papatheofanis F. Lumbar spine fusion for chronic low back pain due to degenerative disc disease: a systematic review. *Spine (Phila Pa 1976)*. 2013;38(7):E409-E422. doi:10.1097/BRS.0b013e3182877f11



34. Manzur MK, Steinhaus ME, Virk SS, Jivanelli B, Vaishnav AS, McAnany SJ, Albert TJ, Iyer S, Gang CH, Qureshi SA. Fusion rate for stand-alone lateral lumbar interbody fusion: a systematic review. *Spine J.* 2020 Nov;20(11):1816-1825. doi: 10.1016/j.spinee.2020.06.006. Epub 2020 Jun 11. PMID: 32535072.
35. Lan T, Hu SY, Zhang YT, et al. Comparison Between Posterior Lumbar Interbody Fusion and Transforaminal Lumbar Interbody Fusion for the Treatment of Lumbar Degenerative Diseases: A Systematic Review and Meta-Analysis. *World Neurosurg.* 2018;112:86-93. doi:10.1016/j.wneu.2018.01.021
36. Chi KY, Cheng SH, Kuo YK, Lin EY, Kang YN. Safety of Lumbar Interbody Fusion Procedures for Degenerative Disc Disease: A Systematic Review With Network Meta-Analysis of Prospective Studies. *Global Spine J.* 2020;2192568220938024. doi:10.1177/2192568220938024
37. Yavin D, Casha S, Wiebe S, et al. Lumbar Fusion for Degenerative Disease: A Systematic Review and Meta-Analysis. *Neurosurgery.* 2017;80(5):701-715. doi:10.1093/neuros/nyw162






**Fig. 1** Flowchart of this systematic review with meta-analysis of prospective studies. RCTs, randomized clinical trials

	Randomization process	Deviations from intended interventions	Missing outcome data	Measurement of the outcome	Selection of the reported result
Challier 2017	+	+	+	?	?
Christensen 2014	+	+	?	?	?
ElShazly 2013	+	+	+	?	?
Etemadifar 2016	+	+	+	?	+
Fariborz 2016	?	?	?	?	-
Hoff 2016	?	+	?	?	+
Høy 2013	+	+	+	?	+
Høy 2017	+	+	?	?	+
Høy 2019	+	+	+	?	+
Isaacs 2016	?	-	?	?	+
Jalalpour 2015	+	+	+	?	+
Li 2013	+	+	+	?	-
Putzier 2016	+	+	+	?	?
Sembrano 2016	?	-	?	?	+
Yang 2016	+	+	?	?	?


**Fig. 2** The risk of bias of each included randomized controlled trial. Low risk is presented as green dot, some concerns as yellow dot, and high risk as red dot




**Fig. 3** The risk of bias of included randomized controlled trials. Bars show percentages across all included RCTs




**Fig. 4** Forest plot and tabulated data illustrating the risk ratio (RR) for fusion rate at 1 year between TLIF, PLF, PLIF and XLIF showing that Other techniques had a better arm fusion rate at 1 year and was therefore superior to TLIF in this respect. *CI* confidence interval; *df* degrees of freedom



**Fig. 5** Forest plot and tabulated data illustrating the risk ratio (RR) for fusion rate at 2 years between TLIF, PLF, PLIF and XLIF showing that there was no significant difference of fusion rate at 2 years between procedures. CI confidence interval;  $df$  degrees of freedom



**Fig. 6** Forest plot and tabulated data illustrating the risk ratio (RR) for adverse events between TLIF, PLF, PLIF, XLIF and no fusion showing that there was no significant difference of adverse events between procedures. *CI* confidence interval; *df* degrees of freedom



**Fig. 7** Forest plot and tabulated data illustrating the risk ratio (RR) for revision rate between TLIF, PLF and XLIF showing that there was no significant difference of revision rate between procedures. *CI* confidence interval; *df* degrees of freedom